Literature DB >> 16890644

Neuromodulatory therapy to improve erectile function recovery outcomes after pelvic surgery.

Arthur L Burnett1, Tom F Lue.   

Abstract

PURPOSE: Erectile dysfunction is a recognized, common adverse consequence of radical prostatectomy as well as various other pelvic surgeries. While a host of management options have been considered to decrease this complication, neuromodulatory therapy has recently been advanced as an intervention that may be applied for this purpose. We evaluated concepts regarding the neuropathic basis for erectile dysfunction following pelvic surgery, principles for establishing neuromodulatory therapy in this clinical context, evidence from preclinical studies supporting neuromodulatory approaches as a therapeutic strategy and the progress of early clinical developments in this field.
MATERIALS AND METHODS: The exercise principally consisted of a current literature search using the National Library of Medicine PubMed Services, a survey of recent abstract proceedings from national meetings relevant to the topic and an Internet online search for current information on federally and privately supported clinical trials specific to this topic. References were made to such key words as neuroprotection, nerve regeneration, nerve growth factors, neurotrophic factors, cavernous nerves, nerve guides and penile erection.
RESULTS: Basic science research and clinical studies support the concept that erectile loss after pelvic surgery is frequently related to neuropathic effects, resulting in penile vascular impairment. An assortment of neurobiological studies using rodent models of cavernous nerve injury have shown nerve reconstitutive actions for a host of neurotrophic substances, including classic neurotrophins, growth hormone, cytokines and atypical neurotrophic mediators. Clinical trials of several proposed neuroprotective and neurotrophic applications have been done or are in progress.
CONCLUSIONS: Erectile dysfunction is a well recognized and yet ineffectively averted complication of pelvic surgery. Neuromodulatory therapy offers a therapeutic approach for addressing the neuropathic changes of the penis that occurs in this context with the goal of maximally preserving erectile function postoperatively. While several specific neuromodulatory applications have gained interest for their potential benefit with pelvic surgery, determining their actual roles awaits the completion of controlled clinical trials.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16890644     DOI: 10.1016/j.juro.2006.04.020

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  11 in total

Review 1.  Three important components in the regeneration of the cavernous nerve: brain-derived neurotrophic factor, vascular endothelial growth factor and the JAK/STAT signaling pathway.

Authors:  Hai-Yang Zhang; Xun-Bo Jin; Tom F Lue
Journal:  Asian J Androl       Date:  2010-12-20       Impact factor: 3.285

2.  2D and 3D T2-weighted MR sequences for the assessment of neurovascular bundle changes after nerve-sparing radical retropubic prostatectomy with erectile function correlation.

Authors:  Valeria Panebianco; Alessandro Sciarra; Marcello Osimani; Danilo Lisi; Mauro Ciccariello; Stefano Salciccia; Vincenzo Gentile; Franco Di Silverio; Roberto Passariello
Journal:  Eur Radiol       Date:  2008-07-24       Impact factor: 5.315

Review 3.  Nerve growth factor modulation of the cavernous nerve response to injury.

Authors:  Anthony J Bella; Guiting Lin; Ching-Shwun Lin; Duane R Hickling; Christopher Morash; Tom F Lue
Journal:  J Sex Med       Date:  2009-03       Impact factor: 3.802

4.  GGF2 is neuroprotective in a rat model of cavernous nerve injury-induced erectile dysfunction.

Authors:  Arthur L Burnett; Sena F Sezen; Ahmet Hoke; Anthony O Caggiano; Jennifer Iaci; Gwen Lagoda; Biljana Musicki; Anthony J Bella
Journal:  J Sex Med       Date:  2015-01-30       Impact factor: 3.802

5.  Anti-inflammatory and anti-fibrotic effects of annexin1 on erectile function after cavernous nerve injury in rats.

Authors:  F N Facio; M F Facio; L F Spessoto; D Pessutti; L O Reis; S G Campos; S Taboga
Journal:  Int J Impot Res       Date:  2016-08-25       Impact factor: 2.896

6.  Improvement of damaged cavernosa followed by neuron-like differentiation at injured cavernous nerve after transplantation of stem cells seeded on the PLA nanofiber in rats with cavernous nerve injury.

Authors:  Jae Heon Kim; Jong Hyun Yun; Eun Seop Song; Seung U Kim; Hong Jun Lee; Yun Seob Song
Journal:  Mol Biol Rep       Date:  2021-04-17       Impact factor: 2.316

7.  Decrease in neuronal nicotinic acetylcholine receptor subunit and PSD-93 transcript levels in the male mouse MPG after cavernous nerve injury or explant culture.

Authors:  Beatrice M Girard; Laura A Merriam; John D Tompkins; Margaret A Vizzard; Rodney L Parsons
Journal:  Am J Physiol Renal Physiol       Date:  2013-09-18

8.  Neurturin enhances the recovery of erectile function following bilateral cavernous nerve crush injury in the rat.

Authors:  Tom F Lue; Anthony J Bella; Thomas M Fandel; Kavirach Tantiwongse; William O Brant; Robert D Klein; Carlos A Garcia
Journal:  J Brachial Plex Peripher Nerve Inj       Date:  2007-03-06

Review 9.  Current rehabilitation strategy: clinical evidence for erection recovery after radical prostatectomy.

Authors:  Arthur L Burnett
Journal:  Transl Androl Urol       Date:  2013-03

10.  The effects of FK1706 on nerve regeneration and bladder function recovery following an end-to-side neurorrhaphy in rats.

Authors:  Wansheng Gao; Xiangfei He; Yunlong Li; Jianguo Wen
Journal:  Oncotarget       Date:  2017-10-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.